

# UPMC Hillman Cancer Center Faculty AACR 2023 Presentations

Friday, April 14

Sessions

**Nadine Hempel, PhD**

“Oxidative stress adaptations during metastasis: Focus on antioxidant enzyme function and regulation”

**3 to 4:30 p.m.**

**Tangerine Ballroom 3 & 4**

**Lan G. Coffman, MD, PhD**

“Studying the impact of the aging stromal microenvironment on cancer initiation”

**4:45 to 6:15 p.m.**

**Room W311 E-H**

Saturday, April 15

**Tullia C. Bruno, PhD**

“The definition of tertiary lymphoid structures: the knowns and the knowledge gap”

**12:30 to 2 p.m.**

**Room W311 E-H**

Sunday, April 16

Session

**Constantinos G. Hadjipanayis, MD**

“Use of fluorescent guided surgery and theranostic applications in neurosurgery”

**1 to 2:30 p.m.**

**Room W311 A-D**

Posters – 1:30 to 5 p.m.

**Section 22**

**Amir Hossein Mohseni, PhD – post-doctoral, University of Pittsburgh**

Session: Cancer-associated Inflammation and Microbiome

644 / 17 - Gut microbiota-derived metabolites as regulators of immunity in pre-cancer

**Section 28**

**Laura P. Stabile, PhD – UPMC Hillman Cancer Center**

Session: Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment

Title: 777 / 19 - Super-resolution imaging of heterochromatin structure detects early events in lung cancer

Minisymposium

**Itay Raphael, PhD**

“T cell receptor (TCR) landscape of childhood brain tumors”

**3 to 5 p.m.**

**Room W307**

Monday, April 17

Sessions

**Taofeek Owonikoko, MD, PhD**

“Putting SCLC in context using emerging clinical and translational insights”

**12:30 to 2 p.m.**

**Room W311 A-D**

**Greg M. Delgoffe, PhD**

**Major Symposium: Immunology, Tumor Biology**

“Leveraging metabolism to improve cancer immunotherapy”

**12:30 to 2 p.m.**

**Valencia B & C**

**Jan Beumer, PhD**

**Novel Antitumor Agents and Targets - Novel Antitumor Agents and Targets**

**2:30 - 4:30 p.m.**

**Room W331**

**Michael J. Becich**

**Forum: Why Share Data and How to Do It Better?: A SWOT Analysis**

“Data sharing leads to more citations, accelerated path to promotion and higher impact of your innovation”

**5 to 6:30 p.m.**

**Room W331**

Posters – 9 a.m. to 12:30 p.m.

**Section 33 - Board 30**

**Yu-Chiao (Chris) Chiu, Ph.D./Li-Ju Wang**

Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science

Abstract Presentation Number: 2094

**Section 21**

**John C. Schmitz**

PO.ET03.06 - Reversal of Drug Resistance

1752 / 17 - Darolutamide reverses osimertinib resistance in non-small cell lung cancer

**Section 21**

**Maria Beecher – Grad student Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA**

1762 / 27 - MALT1 is activated by doxorubicin and mediates therapy resistance in triple-negative breast cancer

**Section 17**

**Bill B. Chen - University of Pittsburgh School of Medicine, Pittsburgh, PA**

Novel Antitumor agents 3

Track(s) Experimental and Molecular Therapeutics

1619 / 9 - Generation of a novel estrogen receptor degrade

**Section 23**

**Julia Knight - University of Pittsburgh School of Medicine**

Track(s) Immunology

PO.IM01.08 - Immunomodulatory Agents and Interventions 1

1798 / 2 - ALDH inhibition as modulator of ovarian tumor associated immune cells

Posters – 1:30 p.m. to 5 p.m.

**Section 7**

**Kaylee Ermine**

PhD Candidate, Zhang Lab

University of Pittsburgh, School of Medicine

"Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance."

**Section 18 – Board 23**

**Jan Beumer**

Title: Pharmacokinetics, bioavailability, and pharmacodynamics of oral triapine

Session Category: Experimental and Molecular Therapeutics

Tuesday, April 18

Sessions

**Meet The Expert: Jeremy Rich, MD**

**Deputy Director, UPMC Hillman Cancer Center**

“Epitranscriptomics and Tumor Metabolism”

**7 to 7:45 a.m.**

**Room W311 E-H**

**Plenary Session**

**Dario Vignali, PhD**

“LAG3: The third checkpoint inhibitor”

**8 to 10 a.m.**

**Vignali – 8:49 to 9:11 a.m.**

**W Hall A 2-3**

**Clinical Trial Minisymposium**

**Jason Luke, MD**

“GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors”

**2:30 to 4:30 p.m.**

**Chapin Theater**

**Forum**

**Monica Baskin, PhD**

“Beyond Platitudes and Proclamations: Meaningful Engagement of Diverse Communities in Cancer Research”

**5 to 6:30 p.m.**

**Room W311 E-H**

Posters – 9 a.m. to 12:30 p.m.

**Section 37**

**Murat Ak**

PO.CL01.04 - Biomarkers of Therapeutic Benefit 4

Track(s) Clinical Research Excluding Trials

4329 / 4 - Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy

**Section 40**

**Sawa Ito**

Track(s) Clinical Research Excluding Trials, Immunology

PO.CL07.02 - Immunomodulatory Agents and Interventions

4418 / 4 - Heterogeneity of IFN- $\gamma$  responsiveness in myeloid malignancies- implication for the possible impact on IFN- $\gamma$  immunotherapy

**Section 40**

**Juliana Hofstatter Azambuja**

Track(s) Clinical Research Excluding Trials, Immunology  
4442 / 28 - Dual benefit of MALT1 blockade in glioblastoma

**Section 41**

**Ronghua Wang**

Track(s) Clinical Research Excluding Trials, Immunology  
PO.CL07.06 - Inflammation, Immunity, and Cancer  
4456 / 9 - Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) inhibition reprogram the tumor microenvironment and suppress tumor growth in hepatocellular carcinoma

**Section 15**

**Vinod Kumar**

Track(s) Experimental and Molecular Therapeutics  
PO.ET03.03 - Drug Resistance in Molecular Targeted Therapies 3  
3853 / 3 - The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in *MET* altered non-small cell lung cancer

Posters – 1:30 to 5 p.m.

**Section 35**

**Jian-Hua Luo**

Tracks – Molecular/Cellular Biology and Genetics  
LB253 / 5 - Long-read single-cell sequencing of liver cancer  
Abstract - EMBARGO

**Section 46**

**Jason Luke**

Track(s) Clinical Trials  
PO.CTP01.01 - Phase I and First-in-Human Clinical Trials in Progress  
CT251 / 14 - Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors  
Abstract - EMBARGO

**Section 17**

**John C. Schmitz**

Track(s) Experimental and Molecular Therapeutics, Chemistry  
PO.ET01.04 - Targeting Protein Kinases and Phosphatases for Therapy 1  
4995 / 8 - Targeting PLK1 effectively suppresses growth of small cell lung cancer

**Section 18**

**Yuzhou Chen**

PO.ET01.05 - Targeting Protein Kinases and Phosphatases for Therapy 2

Track(s) Experimental and Molecular Therapeutics, Chemistry

5015 / 7 - Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer

**Section 19 – Board 28**

**Jan Beumer grad student Josh Deppas poster:**

Title: Toxicological characterization and comparison of ATR inhibitors in mice

Session Category: Experimental and Molecular Therapeutics

Session Title: Theranostics and Radionuclides / Pharmacologic Approaches

Published Abstract Number: 5061

Wednesday, April 19

Posters – 9 a.m. to 12:30 p.m.

**Section 11**

**Kasey R. Cargill**

PO.MCB09.02 - Metabolism and Metabolomics of Cancer

Track(s) Molecular/Cellular Biology and Genetics

6042 / 15 - Targeting metabolic vulnerabilities in MET-driven lung cancer brain metastases

**Section 26**

**Yen Thi-Hai Pham**

Track(s) Population Sciences

PO.PS01.06 - Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors

6449 / 3 - Association between dietary one-carbon metabolism-related nutrients and the risk of colorectal cancer: Findings from the Singapore Chinese Health Study